

EQA round: CC1/24 - Cystatin C

Deadline: 9.2.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(106) Cystatin C	[mg/L]				78							78	78	100	
Sample A		1	0,06	6	78		CVP	1	0,017	23%	0,77	1,23	78	78	100
(1) Abbott		0,985	0,043	4,4	15	0							15		
(46) Erba Lachema		0,93	0,045	4,8	5	0							5		
(60) Roche		0,979	0,039	4	31	0							31		
(162) Siemens (Atellica)		1,06	0,043	4	12	0							12		
Other					15	0							15		
								3x 3, 2x 58, 3x 91, 1x 140, 2x 149, 4x 179							
Sample B		2,77	0,18	6,5	78		CVP	2,77	0,05	23%	2,13	3,41	78	78	100
(1) Abbott		2,8	0,13	4,7	15	0							15		
(46) Erba Lachema		2,77	0,19	6,8	5	0							5		
(60) Roche		2,64	0,079	3	31	0							31		
(162) Siemens (Atellica)		2,92	0,096	3,3	12	0							12		
Other					15	0							15		
								3x 3, 2x 58, 3x 91, 1x 140, 2x 149, 4x 179							